Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Protocol ID
PEPN2121
Disease (Sub Disease)
Multiple tumour types
Diagnosis Stage
Newly diagnosed
Relapsed/Refractory
Relapsed/Refractory
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Months and older
International registry ID's
NCT05286801
| Study Title | A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors |
|---|---|
| Protocol ID | PEPN2121 |
| Disease (Sub Disease) | Multiple tumour types |
| Diagnosis Stage | Newly diagnosed Relapsed/Refractory |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT05286801 |
| Trial Status | Preparing to Open |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 12 Months and older |
| International registry ID's | NCT05286801 |